title: Contrasting effects of IFNbeta and IVIG in children with central and peripheral demyelination.
abstract: Reported are three children with MS who responded dramatically to interferon-beta (IFNbeta) therapy. While on immunomodulatory therapy, they developed chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) that responded to IV immunoglobulin (IVIG) administration. These cases emphasize two interesting observations: 1) IFNbeta treatment did not prevent development of CIDP; 2) CIDP in the context of MS responded to IVIG, even though IVIG had no therapeutic effect on the central demyelinating disease.
authors.affiliation: Department of Neurology, Mayo Clinic, Rochester, MN 55902, USA.
authors.forename: I
authors.initials: I
authors.lastname: Pirko
authors.forename: N L
authors.initials: NL
authors.lastname: Kuntz
authors.forename: M
authors.initials: M
authors.lastname: Patterson
authors.forename: B M
authors.initials: BM
authors.lastname: Keegan
authors.forename: B G
authors.initials: BG
authors.lastname: Weinshenker
authors.forename: M
authors.initials: M
authors.lastname: Rodriguez
mesh_terms: D020274:Autoimmune Diseases of the Nervous System / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009103:Multiple Sclerosis / Q000150:complications / Q000628:therapy*; D009928:Organ Specificity; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000150:complications / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D016756:Immunoglobulins, Intravenous; D016899:Interferon-beta; D000068556:Interferon beta-1a